Academia

The phase 2 ZUMA-3 trial of brexucabtagene autoleucel showed that it is possible to intervene early to prevent some toxicity, said Bijal Shah, MD, associate member in the Department of Malignant Hematology at Moffitt Cancer Center.

Classification criteria developed using machine learning will allow doctors to conduct disease-specific research about this collection of inflammatory eye diseases.

The study's lead author said researchers have searched for a generation for an effective therapy to give to high-risk patients with renal cell carcinoma after initial surgery for the tumor.

Also, phase 2 results for atezolizumab presented during the 2021 Annual Meeting of the American Society of Clinical Oncology could help patients in same setting who need another option.

Martin J. Edelman, MD, chair of the Department of Hematology/Oncology and associate director for Translational Research at the Fox Chase Cancer Center in Philadelphia, Pennsylvania, discusses the the nuances of rescinded indications in small-cell lung cancer.

Recent coverage from Targeted Oncology® highlights how combination therapies are impacting the treatment spectrum for chronic lymphocytic leukemia (CLL).

Technological innovation is helping to reinvent the traditional health economics and outcomes research (HEOR) field as traditional and new players partner to leverage data sources.

The COVID-19 pandemic brought together the world and taught health systems how to be resilient and adapt to both predictable and unpredictable changes, said the panelists during the plenary on day 1 of Virtual ISPOR 2021.

Two top cardiologists debated evidence involving one clinical trial for omega-3 fatty acids, with implications for another, the REDUCE-IT study for icosapent ethyl (Vascepa).

The Dapagliflozin in Respiratory Failure in Patients With COVID-19 trial is the first phase 3 study to examine whether this SGLT2 inhibitor, which has proven effective for multiple chronic conditions, might be similarly useful in an acute setting.

New research is helping to move the field forward for diffuse large B-cell lymphoma (DLBCL).

Updates from 2 recent medical meetings about links between the gut, psoriasis, and other skin disease, as well as the risk of COVID-19.

The 4-day annual meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research—will cover a wide range of topics. Here are 5 themes to keep an eye out for.

BK virus–specific T cells from healthy donors were an effective and safe off-the-shelf treatment for patients with leukemia or lymphoma who developed a painful and common complication after allogeneic hematopoietic stem cell transplantation.

The summit will address priority patient inputs for comparative effectiveness research and health technology assessments.

Skin cancer is one of the most common diseases dermatologists deal with on a daily basis, and as global rates increase, it is clear that climate change is a contributory factor, said Eva R. Parker, MD, FAAD, assistant professor of dermatology, Vanderbilt University Medical Center, during her session at the American Academy of Dermatology Virtual Meeting Experience.

Posters presented at the American Academy of Dermatology Virtual Meeting Experience show ruxolitinib cream was effective at treating atopic dermatitis (AD) regardless of previous treatments and in patients with more severe disease.

While the introduction of sodium glucose co-transporter 2 (SGLT2) inhibitors has benefitted patients with type 2 diabetes and impacted guidelines globally, these expensive therapies have managed care implications, explained Richard E. Pratley, MD, of AdventHealth Diabetes Institute and Johns Hopkins University School of Medicine.

Metastatic breast cancer has a poor prognosis, but emerging targeted therapies are providing some progress in the treatment of the disease, explained Filipa Lynce, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School.

Research presented at the American Academy of Neurology's annual meeting indicates some air pollutants may be associated with increased rates of migraine prevalence and severity.

The researchers focused on immunotherapy combinations, which they say may hold promise in the treatment of late-stage or recurrent endometrial cancer (EC).

A better understanding of the genetic etiology of pulmonary arterial hypertension and its molecular variants is needed to develop better therapies for the disease, which has no agents available that can reverse or halt it.

The study identifies the tumor-suppressing protein p53 as a working partner of “speckles,” nuclear structures that contain proteins and RNA involved in gene expression.

An ongoing multicenter study in Japan will evaluate reductions in pulmonary vascular resistance 8 months after initiating the combination therapy in pulmonary arterial hypertension.

Penn Medicine's Stephen Schuster, MD, offers an overview of an eventful year in CAR T-cell therapy at the NCCN Virtual Annual Meeting.

Researchers analyzed 2 cohorts of patients with chronic obstructive pulmonary disease (COPD) to characterize who is most at risk for developing hypercapnia and who could most benefit from at-home noninvasive inhalation therapy.

The specialization program will teach fundamentals and offer real-world examples of value-based care through an online program.

While diagnostic algorithms have evolved in the last decade, there remains an urgent need for innovative therapeutic options to treat systemic sclerosis with pulmonary arterial hypertension.

Cutting-edge genetic tools diagnosed 83% of Irish patients with polycystic kidney disease (PKD), identified 36 novel variants, and discovered that seemingly unrelated individuals with the same variant likely inherited it from a common ancestor.

Nanotherapies have the potential to overcome the blood-brain barrier and the blood-cerebrospinal fluid barrier, representing a possible treatment opportunity for rare diseases.